95 related articles for article (PubMed ID: 19286253)
21. Proteins interacting with the tuberous sclerosis gene products.
Rosner M; Freilinger A; Hengstschläger M
Amino Acids; 2004 Oct; 27(2):119-28. PubMed ID: 15351877
[TBL] [Abstract][Full Text] [Related]
22. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis.
Curatolo P; Bombardieri R; Jozwiak S
Lancet; 2008 Aug; 372(9639):657-68. PubMed ID: 18722871
[TBL] [Abstract][Full Text] [Related]
24. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.
Astrinidis A; Senapedis W; Henske EP
Hum Mol Genet; 2006 Jan; 15(2):287-97. PubMed ID: 16339216
[TBL] [Abstract][Full Text] [Related]
25. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
[TBL] [Abstract][Full Text] [Related]
26. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
27. The cell cycle and tuberous sclerosis.
Hengstschläger M; Rosner M
Prog Cell Cycle Res; 2003; 5():43-8. PubMed ID: 14593699
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
29. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
30. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications.
Trelinska J; Fendler W; Dachowska I; Kotulska K; Jozwiak S; Antosik K; Gnys P; Borowiec M; Mlynarski W
Orphanet J Rare Dis; 2016 Sep; 11(1):129. PubMed ID: 27680012
[TBL] [Abstract][Full Text] [Related]
31. Tuberin activates the proapoptotic molecule BAD.
Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
[TBL] [Abstract][Full Text] [Related]
32. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
33. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
34. Hamartin and tuberin modulate gene transcription via beta-catenin.
Jozwiak J; Wlodarski P
J Neurooncol; 2006 Sep; 79(3):229-34. PubMed ID: 16552619
[TBL] [Abstract][Full Text] [Related]
35. Hamartin and tuberin expression in human tissues.
Johnson MW; Kerfoot C; Bushnell T; Li M; Vinters HV
Mod Pathol; 2001 Mar; 14(3):202-10. PubMed ID: 11266527
[TBL] [Abstract][Full Text] [Related]
36. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis.
Jóźwiak S; Kwiatkowski D; Kotulska K; Larysz-Brysz M; Lewin-Kowalik J; Grajkowska W; Roszkowski M
J Child Neurol; 2004 Feb; 19(2):102-6. PubMed ID: 15072102
[TBL] [Abstract][Full Text] [Related]
37. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
38. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
39. The neurobiology of the tuberous sclerosis complex.
Marcotte L; Crino PB
Neuromolecular Med; 2006; 8(4):531-46. PubMed ID: 17028374
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis complex.
Henske EP; Jóźwiak S; Kingswood JC; Sampson JR; Thiele EA
Nat Rev Dis Primers; 2016 May; 2():16035. PubMed ID: 27226234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
